Using machine learning and advanced data science to revolutionise clinical trial data management

利用机器学习和先进的数据科学彻底改变临床试验数据管理

• 批准号: 10067048
• 金额: $ 38.94万
• 依托单位: LINDUS HEALTH LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10067048
• 关键词: Using; machine; learning; advanced; data

Combining innovations in machine learning and data science and with relevance to all 35K human clinical trials performed globally each year, Lindus aim to develop the first software solution capable of automated real time clinical trial data capture, analysis and prediction - exploiting known gaps in clinical data management (defined as the collection, integration and validation of trial data).The approach has been specifically designed to address stated challenges cited by trial sponsors (typically represented by pharmaceutical and biotech companies) in response to an increasing demand for fast-track drug development processes, a drive for improved patient safety and improved quality of data outputs. The approach significantly advances current clinical data management processes which centre around manual paper-based data input and electronic data capture with interpretation typically performed retrospectively (in some cases months after trial completion), providing greater risk of issues in data quality and an inability to identify risks/quality/safety issues as and when they occur. With the potential to accelerate delivery and reduce clinical trial costs (by up to 25%), the proposed solution offers significant growth potential as a disruptive innovation that fully meets the needs of trial sponsors and regulators. It will be exploited globally by an established but fast-growing contract research organisation who have pioneered the use of AI in clinical trial design and delivery as part of an established end-to-end trial delivery platform (existing functions include study design, patient recruitment capability and trial management) with a range of customers ready to adopt the product. Innovate UK support will accelerate the proposed 15-month workplan allowing Lindus (named after James Lind who pioneered the first clinical trial in the 18th century) to gain a dominant position in a Clinical Data Management System Market currently valued at USD1.9 billion with planned exploitation across the UK, EU and U.S.

结合机器学习和数据科学的创新，并与每年全球进行的所有35，000项人体临床试验相关，Lindus的目标是开发第一个能够自动化真实的时间临床试验数据采集，分析和预测的软件解决方案-利用临床数据管理中的已知差距（定义为集合，试验数据的整合和验证）。该方法专门设计用于解决试验申办者提出的挑战（通常以制药和生物技术公司为代表），以应对对快速药物开发流程日益增长的需求，提高患者安全性和提高数据输出质量的驱动力。该方法显著推进了当前的临床数据管理流程，该流程以手动纸质数据输入和电子数据采集为中心，通常进行回顾性解释（在某些情况下，在试验完成后数月），提供了更大的数据质量问题风险，并且无法在发生时识别风险/质量/安全性问题。该解决方案具有加快交付和降低临床试验成本（最高可降低25%）的潜力，作为完全满足试验申办者和监管机构需求的颠覆性创新，具有显著的增长潜力。它将在全球范围内由一家成熟但快速增长的合同研究组织利用，该组织率先在临床试验设计和交付中使用人工智能，作为已建立的端到端试验交付平台的一部分（现有功能包括研究设计，患者招募能力和试验管理），一系列客户准备采用该产品。Innovate UK的支持将加速拟议的15个月工作计划，使Lindus（以18世纪世纪第一次临床试验的先驱James Lind命名）在临床数据管理系统市场中获得主导地位，目前价值19亿美元，计划在英国，欧盟和美国进行开发。